Merck spins off assets to focus on main growth drivers: cancer drugs, vaccines
The spin-off is a culmination of the drugmaker’s strategy of concentrating on a few key areas, particularly oncology
05 February 2020 - 18:27
Bengaluru — Merck said on Wednesday it will spin off its women’s health, biosimilar drugs and older products into a separate publicly traded company as it tightens its focus on growth drivers such as cancer drug Keytruda and vaccines.
The new company’s assets make up about 15% of Merck’s total sales and about half of its drugs that treat people...
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Subscribe now to unlock this article.
Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).
There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.
Cancel anytime.
Questions? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now.